Stockreport

Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]

Korro Bio, Inc.  (KRRO) 
PDF Korro Bio, Inc. Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopath [Read more]